Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL8866463 | 0.89 | SIGMAR1 (0.44) | OPRM1KCNH2SIGMAR1 | |
| Maleic Acid SCHEMBL8866452 | 0.89 | SIGMAR1 (0.44) | OPRM1KCNH2SIGMAR1 | |
| SCHEMBL9279009 | 0.85 | OPRM1 (0.42) | OPRM1KCNH2SIGMAR1 | |
| SCHEMBL9252531 | 0.80 | — | — | |
| SCHEMBL1326512 | 0.77 | — | — | |
| SCHEMBL9820569 | 0.76 | — | — | |
| SCHEMBL8342295 | 0.76 | — | — | |
| SCHEMBL19852102 | 0.75 | — | — | |
| Ethylene SCHEMBL9699905 | 0.75 | — | — | |
| SCHEMBL21601991 | 0.74 | OPRM1 (0.37) | OPRM1KCNH2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0311313-B1 | Heterocyclic spiro compounds and their preparation | YAMANOUCHI PHARMA CO LTD (JP) | 1995-05-10 | — | — | EP | claimed |
| US-5412096-A | Treatment of senile dementia, Alzheimer*s disease, cholinergic activators | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1995-05-02 | — | — | US | claimed |
| US-RE34653-E | 1-oxa-8-azaspiro/4,5/decane compounds | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1994-07-05 | — | — | US | claimed |
| US-4940795-A | Heterocyclic spiro compounds and methods for preparing the same | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1990-07-10 | — | — | US | claimed |
| EP-0311313-A2 | Heterocyclic spiro compounds and their preparation | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1989-04-12 | — | — | EP | claimed |
| US-20090082381-A1 | Percutaneously Absorbable Ophthalmic Preparation | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20080306103-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND NOVEL COMPOUNDS USEFUL THEREFOR | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH | 2008-12-11 | — | — | US | disclosed |
| US-7439251-B2 | Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 2008-10-21 | — | — | US | disclosed |
| EP-1917964-A1 | PERCUTANEOUSLY ABSORBABLE OPHTHALMIC PREPARATION | Senju Pharmaceutical Co., Ltd. (JP) | 2008-05-07 | — | — | EP | disclosed |
| EP-1507765-A4 | METHODS AND COMPOSITIONS FOR TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND NOVEL COMPOUNDS USEFUL THEREFOR | ISRAEL INST BIOLOG RES (IL) | 2006-11-02 | — | — | EP | disclosed |
| US-7049321-B2 | Methods and pharmaceutical compositions for treatment of central and peripheral nervous system disorders and compounds useful therefor | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 2006-05-23 | — | — | US | disclosed |
| US-20060052406-A1 | Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor | ISREAL INSTITUTE FOR BIOLOGICAL RESEARCH (US) | 2006-03-09 | — | — | US | disclosed |
| US-5412096-A | Treatment of senile dementia, Alzheimer*s disease, cholinergic activators | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1995-05-02 | — | — | US | disclosed |
| US-RE34653-E | 1-oxa-8-azaspiro/4,5/decane compounds | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1994-07-05 | — | — | US | disclosed |
| EP-0490901-A1 | NOVEL SPIROFURANE DERIVATIVES | Astra Aktiebolag (SE) | 1992-06-24 | — | — | EP | disclosed |
| US-5041549-A | Cholinergin agents | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1991-08-20 | — | — | US | disclosed |
| US-4996210-A | Cognition activators, nervous system disorders; muscarinic acetylcholine receptor agonists; 2,8-dimethyl-3-methylene-1-oxa-8-azaspiro[4.5]decane for example | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1991-02-26 | — | — | US | disclosed |
| WO-1990015804-A1 | NOVEL SPIROFURANE DERIVATIVES | FISONS CORPORATION (US) | 1990-12-27 | — | — | WO | disclosed |
| US-4940795-A | Heterocyclic spiro compounds and methods for preparing the same | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1990-07-10 | — | — | US | disclosed |
| EP-0311313-A2 | Heterocyclic spiro compounds and their preparation | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1989-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306103-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND NOVEL COMPOUNDS USEFUL THEREFOR | PMP22, PYGB, GAP43 | OPRM1 745/4885KCNH2 2100/4885SIGMAR1 751/4885 |
| US-20090082381-A1 | Percutaneously Absorbable Ophthalmic Preparation | SLC26A4, SLC5A11, REN | OPRM1 2536/4885KCNH2 1573/4885SIGMAR1 1768/4885 |
| US-20060052406-A1 | Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor | PMP22, PYGB, GAP43 | OPRM1 745/4885KCNH2 2100/4885SIGMAR1 751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.